Kammi Fox-Kay, Cathy Simmons, and Lauren Welch describe their perspectives on advances in NSCLC treatment over the past decade, focusing on the development of targeted agents and the discovery of new molecular targets for therapy, as well as the expanding use of immunotherapy as first-line therapy for NSCLC. They describe this as a “thrilling time” in NSCLC treatment where they can reassure their patients that they will be able to live longer with their disease, even at stage III or IV.
Reflecting on Advances in NSCLC Treatment Over the Past 10 Years
Thoracic Oncology Nurse Navigator
Community Healthcare System
Munster, Indiana
Community Healthcare System
Munster, Indiana
Thoracic Oncology Navigator
Sarah Cannon Cancer Institute
Plano, Texas
Sarah Cannon Cancer Institute
Plano, Texas
Nurse Practitioner
Tennessee Oncology
Nashville, TN
Tennessee Oncology
Nashville, TN
Get TOP in Your Inbox
Stay up to date with the latest oncology pharmacy news and insights by subscribing to our e-newsletter!